Xenon shares fall following depression trial pause

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

By Jonathan Gardner • Sept. 18, 2026

This week in charts: GSK’s China deals, the $300M IPO club and selling the news

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.

By Ben Fidler • Sept. 18, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

By BioPharma Dive staff • Sept. 18, 2026

Electra amasses $350M in biotech’s latest big IPO

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.

By Gwendolyn Wu • Sept. 17, 2026

Lisata deal propels Marea’s drug pipeline to Wall Street

Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

By Delilah Alvarado • Sept. 17, 2026

Novo partners with Orbis, deepening investment in oral peptide drugs

The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

By Jonathan Gardner • Sept. 17, 2026

North Immunology joins biotech reverse merger boom with Aethlon deal

Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.

By Kristin Jensen • Sept. 17, 2026

Roche, Dualitas team up to find bispecific drugs for immune diseases

Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments. 

By Gwendolyn Wu • Sept. 17, 2026

Novartis to pay $125M for blood-brain barrier crossing platform

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

By Delilah Alvarado • Sept. 16, 2026

Sling banks $123M for an experimental thyroid eye disease pill

A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

By Gwendolyn Wu • Sept. 16, 2026

Skyhawk racks up more support for Huntington’s drug

The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

By Jacob Bell • Sept. 16, 2026

FDA clears first generic radioligand drug; Sionna turns to layoffs

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

By BioPharma Dive staff • Sept. 15, 2026

This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.

By Jacob Bell • Sept. 11, 2026

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

By BioPharma Dive staff • Sept. 11, 2026

Tyra disappoints investors with bladder cancer data

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

By Jonathan Gardner • Sept. 9, 2026

Kura spins diabetes work into a Lilly-backed biotech startup

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

By Gwendolyn Wu • Sept. 9, 2026

A new immuno-oncology play raises $225M for a next-generation drug

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.

By Gwendolyn Wu • Sept. 9, 2026

Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.

By Delilah Alvarado • Sept. 8, 2026

Moonwalk reloads with $70M and new RNAi prospects for obesity

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

By Gwendolyn Wu • Sept. 8, 2026

BrainChild hauls in $116M to make cell therapies for childhood brain cancers

Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.

By Gwendolyn Wu • Sept. 8, 2026

This week in charts: China deals, stock flatlines and Lilly’s M&A spree

Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.

By Gwendolyn Wu • Sept. 4, 2026

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

By BioPharma Dive staff • Sept. 4, 2026

An AI drug specialist zeroes in on rare forms of obesity

Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.

By Gwendolyn Wu • Sept. 3, 2026

GSK wagers up to $1.3B on a different kind of cancer drug

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

By Delilah Alvarado • Sept. 3, 2026

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

By Jonathan Gardner • Sept. 3, 2026